References
- Petrich A, Kahl B, Bailey H, Kim K, Turman N, Juckett M. Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome. Leuk Lymphoma 2008; 49: 57–61
- Koeffler H P, Hirji K, Itri L. 1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep 1985; 69: 1399–1407
- Motomura S, Kanamori H, Maruta A, Kodama F, Ohkubo T. The effect of 1-hydroxyvitamin D3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes. Am J Hematol 1991; 38: 67–68
- Mellibovsky L, Díez A, Pérez-Vila E, Serrano S, Nacher M, Aubía J, et al. Vitamin D treatment in myelodysplastic syndromes. Br J Haematol 1998; 100: 516–520
- Koeffler H P, Aslanian N, O'Kelly J. Vitamin D (2) analog (Paricalcitol; Zemplar) for treatment of myelodysplastic syndrome. Leuk Res 2005; 11: 1259–1262
- Molnar I, Stark N, Lovato J, Powell B L, Cruz J, Hurd D D, et al. Treatment of low-risk myelodysplastic syndromes with high-dose daily oral cholecalciferol (2000 – 4000 IU vitamin D(3)). Leukemia 2007; 5: 1089–1092
- Tiffany N M, Ryan C W, Garzotto M, Wersinger E M, Beer T M. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study. J Urol 2005; 174: 888–892
- Gombart A F, Borregaard N, Koeffler H P. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J 2005; 19: 1067–1077
- Wang T T, Nestel F P, Bourdeau V, Nagai Y, Wang Q, Liao J, et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004; 173: 2909–2912